Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat QT/QTc Evaluation in Stable CAD
NCT03504982Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of vericiguat in coronary artery disease (CAD) (2 arms), sponsored by Bayer. Primary endpoint: QT interval corrected according to Fridericia at Day 56. Started May 2018; status: completed.
02
Drugs
vericiguat
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03504982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504982.